Press Release: IOVANCE (IOVA) ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into Iovance Biotherapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Iovance (IOVA) To Contact Him Directly To Discuss Their Options If you are a long-term stockholder in Iovance between May 9, 2024 and May 8, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore…
Selskabsmeddelelse nr. 28/2025København, den 8. oktober 2025 Unlimit Group A/S ("Unlimit Group" eller "Selskabet") ønsker at præcisere en udtalelse afgivet i et interview med dagbladet Børsen torsdag den 2. oktober 2025, hvori det fejlagtigt fremgår, at Selskabet allerede har solgt sin ejerandel i SmartShop Danmark ApS ("SmartShop Danmark").
ENCINO, Calif., Oct. 08, 2025 (GLOBE NEWSWIRE) -- NETSOL Technologies, Inc. (Nasdaq: NTWK), a provider of AI-powered solutions and services enabling OEMs, dealerships and financial institutions to sell, finance and lease assets, announced the launch of Check AI – its next-generation AI-powered credit decisioning engine designed to revolutionize the credit underwriting process.
Basel, Switzerland, October 08, 2025 – NUCLIDIUM AG, a clinical-stage radiopharmaceutical company developing a proprietary copper-based theranostic platform, today announced positive clinical data from the ongoing Phase I/II trial (NCT06455358) evaluating its novel copper-radiolabeled PET tracer, 61Cu-TraceNetTM ([61Cu]Cu-NODAGA-LM3) in patients with SSTR-positive gastroenteropancreatic and bronchopulmonary neuroendocrine tumors (GEP & BP-NETS). Principal investigator Dr. Guillaume Nicolas,…
MILANO, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), azienda biofarmaceutica focalizzata sullo sviluppo e la commercializzazione di nuove terapie per malattie genetiche rare e ultra-rare, ha annunciato oggi che l'AIFA (Agenzia Italiana del Farmaco) ha esteso il rimborso di Evkeeza® (evinacumab) per il trattamento di pazienti pediatrici a partire dai 6…
